The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes

Leukemia

Volumn 13, Issue 3, 1999, Pages 393-399

  Tamaki, H ^b   Ogawa, H ^b   Ohyashiki, K ^b   Ohyashiki, H ^b   Iwama, H ^b   Inoue, K ^b   Soma, T ^b   Oka, Y ^b   Tatekawa, T ^b   Oji, Y ^b   Tsuboi, A ^b   Kim, E H ^b   Kawakami, M ^b   Fuchigami, K ^b   Tomonaga, M ^b   Toyama, K ^b   Aozasa, K ^b   Kishimoto, T ^b   Sugiyama, H ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b NONE

Author keywords

MDS; Wilms' tumor gene; WT1

Indexed keywords

TUMOR MARKER;

ALLOTRANSPLANTATION; ARTICLE; BLAST CELL; CANCER GENETICS; CANCER SURVIVAL; DISEASE COURSE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; NEPHROBLASTOMA; PRIORITY JOURNAL; REFRACTORY ANEMIA; STEM CELL TRANSPLANTATION;

EID: 0033049268     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401341     Document Type: Article

References (24)

1. Goasguen JE, Bennett JM. Classification and morphologic features of the myelodysplastic syndromes. Semin Oncol 1992; 19: 4-13.
2. Ganser A, Hoelzer D. Clinical course of myelodysplastic syndromes. Hematol Oncol Clin N Am 1992; 6: 607-618.
3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Gallon DAG. Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
4. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH, Jones C, Housman DE. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509-520.
5. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GAP. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990; 343: 774-778.
6. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K, Kyo T, Dohy H, Nakauchi H, Ishidate T, Akiyarna T, Kishimoto T. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071-3079.
7. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, Miyake S, Tamaki H, Oji Y, Yamagami T, Tatekawa T, Soma T, Kishimoto T, Sugiyama H. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89: 1405-1412.
8. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992; 6: 405-409.
9. Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, Miyoshi I. Expression of the candidate Wilms' tumor gene, WT1, in human leukemia cells. Leukemia 1993; 7: 970-977.
10. Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia 1994; 8: 2139-2143.
11. Menssen HD, Renkl H-J, Rodeck U, Maurer J, Notter M, Schwartz S, Reinhardt R, Thiel E. Presence of Wilm's tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995; 9: 1060-1069.
12. Tamaki H, Ogawa H, Inoue K, Soma T, Yamagami T, Miyake S, Oka Y, Oji Y, Tatekawa T, Tsuboi A, Tagawa S, Kitani T, Miwa H, Kita K, Aozasa K, Kishimoto T, Sugiyama H. Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia. Blood 1996; 88: 4396-4398.
13. Inoue K, Ogawa H, Yamagami T, Soma T, Tani Y, Tatekawa T, Oji Y, Tamaki H, Kyo T, Dohy H, Hiraoka A, Masaoka T, Kishimoto T, Sugiyama H. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996; 88: 2267-2278.
14. Sanz GF, Sanz MA, Vallespi T, Canizo M. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395-408.
15. Aul C, Gatterman N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992; 6: 52-59.
16. Toyama K, Ohyashiki K, Yoshida Y, Abe T, Asano S, Hirai H, Hirashima K, HottaT, Kuramoto A, Kuriya S, Miyazaki T, Kakishita E, Mizoguchi H, Okada M, Shirakawa S, Takaku F, Tomonaga M, Uchino H, Yasunaga K, Nomura T. Clinical implications of chromosomal abnormalities in 401 patients with MDS. A multicentric study in Japan. Leukemia 1993; 7: 499-508.
17. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, Bauters F, Fenaux P. Cytogenetic analysis has strong prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993; 7: 1315-1323.
18. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
19. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukemia. Nature 1987; 328: 342-344.
20. Hardy CL, Omoto E, Tavassoli M. Measurement of homing receptors on the surface of leukemic and nonleukemic cell lines. Pathobiology 1990; 58: 179-184.
21. Oguma S, Yoshida Y, Uchino H, Maekawa T, Nomura T, Mizoguchi H, and the Refractory Anemia Study Group of the Ministry of Health and Welfare. Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Leukemia Res 1995; 19: 219-225.
22. Engel H, Goodacre A, Keyhani A, Jiang S, Van NT, Kimmel M, Sanchez-Williams G, Andreeff M. Minimal residual disease in acute myelogenous leukaemia and myelodysplastic syndromes: a follow-up of patients in clinical remission. Br J Haematol 1997; 99: 64-75.
23. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, Kudoh T, Akiyama T, Murakami A, Maekawa T, Kishimoto T. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 1996; 87: 2878-2884.
24. Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T, Oji Y, Tsuboi A, Kim EH, Kawakami M, Akiyama T, Kishimoto T, Sugiyama H. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998; 91: 2969-2976.